Arvana, Inc. Announces Court-Approved Settlement Agreement with J.P. Carey Enterprises, Inc.

Key Points:

• Settlement Agreement Executed: On January 13, 2026, Arvana, Inc. (“the Company”) entered into a Settlement Agreement and Stipulation with J.P. Carey Enterprises, Inc. (“JPCarey”).
• Court Approval and Fairness Hearing: A court fairness hearing was held April 7, 2026, under Section 3(a)(10) of the Securities Act. On April 11, 2026, the court entered an Agreed Order approving the settlement and exchange/issuance of securities.
• Exempt from Registration: The court found the settlement to be fair, adequate, reasonable, and the product of arm’s-length negotiations. The issuance and exchange of the Settlement Shares, including additional shares for fees and expenses, are exempt from registration under Section 3(a)(10) of the Securities Act and Florida Statutes Section 517.061(1)(b).
• Settlement Shares Issuance: Following court approval, Arvana must deliver the Settlement Shares within three trading days, accompanied by a legal opinion confirming their validity, that they are fully paid and non-assessable, exempt from registration, and may be issued without restrictive legend. Shares will be delivered electronically via book-entry or Depository Trust Company (DTC) systems, including FAST or DWAC.
• Beneficial Ownership Limitation: JPCarey cannot beneficially own more than 4.99% of Arvana’s outstanding common stock at any time. Settlement Shares will be issued in multiple tranches to ensure compliance with this limitation.
• Transfer Agent Directions: The court order directs Arvana and its transfer agent to issue the Settlement Shares without restrictive legend, delivered via book-entry or DTC, upon satisfaction of customary transfer agent requirements and receipt of legal opinion.
• Covenants and Obligations: Arvana is required to maintain sufficient authorized shares to meet its obligations under the Settlement Agreement, including increasing its authorized share capital if necessary. The agreement includes customary representations, warranties, and covenants.
• Termination Events: The Settlement Agreement may be terminated if certain events occur, including failure by Arvana to deliver shares on time, failure to obtain court approval, trading suspensions, or insolvency-related events.
• Release of Claims: Upon full issuance of Settlement Shares, both parties will mutually release all claims related to the underlying dispute. The agreement is a compromise of disputed claims and does not constitute an admission of liability by either party.
• Exhibit Filed: The Settlement Agreement is filed as Exhibit 10.1 to this Form 8-K.

Shareholder Information and Potential Price Sensitivity:

• Issuance of New Shares: The Settlement Agreement will result in the issuance of new common shares to JPCarey. This could potentially dilute existing shareholders depending on the number of shares issued and the tranches required by the 4.99% ownership limitation.
• No Restrictive Legend: Shares issued to JPCarey will be freely tradeable, which means they can be sold into the market without restriction. This could impact the share price if a large number of shares are sold.
• Obligation to Increase Authorized Share Capital: If Arvana does not have enough authorized shares to fulfill the agreement, it must take action to increase its authorized capital, which may require shareholder approval and could affect share value.
• Court Retains Jurisdiction: The court retains jurisdiction to enforce the terms of the settlement, offering additional legal protection but also ongoing oversight.
• Potential Termination Events: If Arvana fails to deliver the shares or satisfy the agreement terms, the settlement could be terminated, potentially resulting in further litigation or financial impact.

Additional Details:

• The report confirms no written communications under Rule 425, no soliciting material under Rule 14a-12, no pre-commencement tender offer communications under Rule 14d-2(b) or 13e-4(c).
• Arvana is not an emerging growth company and has not elected to use the extended transition period for new accounting standards.
• Details of the agreement, court order, and related exhibits are available for investors and should be reviewed for full understanding of potential impacts.
• The settlement is explicitly stated to not be an admission of liability by either party.
• Signature: The report is signed by James Kim on behalf of Arvana, Inc., dated April 22, 2026.

Investor Impact

The issuance of new, freely tradeable shares to settle a legal dispute is a material event for Arvana, Inc. shareholders. The potential dilution, the ability for JPCarey to sell shares without restriction, and the need to possibly increase authorized share capital are all factors that could affect the share price and shareholder value. Investors should monitor subsequent disclosures and consider the potential for increased share supply in the market.

Disclaimer: This article is based on public filings and does not constitute investment advice. Investors should review the full Form 8-K, Settlement Agreement, and related exhibits and consult their own advisors before making any investment decisions. The information herein is for informational purposes only and may not reflect all risks or impacts associated with the disclosed events.

View ARVANA INC Historical chart here